Table III.
Log-rank test and Cox proportional HRs for overall survival.
| Receptor status | ||||||
|---|---|---|---|---|---|---|
| Primary tumor | Metastatic tumor | Disease-free interval Means ± SE (years) | Overall survival Means ± SE (years) | P-value | HR (95% CI) | P-value |
| Estrogen receptor | ||||||
| Positive | Positive | 5.4±0.8 | 14.8±1.4 | 0.005 | 1 | 0.008 |
| Negative | 4.1±1.2 | 7.4±1.2 | 3.44 (1.36–8.33) | |||
| Negative | Positive | 6.5±2.6 | 15.3±3.7 | 0.542 | 1 | 0.544 |
| Negative | 2.7±0.6 | 10.8±1.7 | 1.56 (0.38–6.66) | |||
| Progesterone receptor | ||||||
| Positive | Positive | 6.0±1.0 | 17.5±1.7 | 0.000 | 1 | 0.001 |
| Negative | 3.7±0.0 | 7.3±0.8 | 8.33 (2.32–33.3) | |||
| Negative | Positive | 7.7±2.1 | 19.3±3.6 | 0.116 | 1 | 0.018 |
| Negative | 2.7±0.0 | 9.6±1.4 | 6.66 (1.36–33.3) | |||
HR, hazard ratio; SE, standard error; CI, confidence interval.